Integrated Biopharma Price Prediction
| INBPDelisted Stock | USD 0.23 0.01 4.55% |
Oversold Vs Overbought
44
Oversold | Overbought |
Integrated Biopharma stock price prediction is an act of determining the future value of Integrated Biopharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Integrated Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Integrated Biopharma and does not consider all of the tangible or intangible factors available from Integrated Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with Integrated Biopharma, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether otc price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Integrated Biopharma based on different types of headlines from major news networks to social media. The Integrated stock price prediction module provides an analysis of price elasticity to changes in media outlook on Integrated Biopharma over a specific investment horizon. Using Integrated Biopharma hype-based prediction, you can estimate the value of Integrated Biopharma from the perspective of Integrated Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Integrated Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Integrated Biopharma to buy its otc stock at a price that has no basis in reality. In that case, they are not buying Integrated because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell otc stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Integrated Biopharma after-hype prediction price | USD 0.29 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as otc price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Integrated |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Integrated Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Integrated Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Integrated Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Integrated Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of OTC Stock prices, such as prices of Integrated Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Integrated Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Integrated Biopharma's otc stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Integrated Biopharma's historical news coverage. Integrated Biopharma's after-hype downside and upside margins for the prediction period are 0.01 and 5.80, respectively. We have considered Integrated Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Integrated Biopharma is out of control at this time. Analysis and calculation of next after-hype price of Integrated Biopharma is based on 3 months time horizon.
Integrated Biopharma OTC Stock Price Prediction Analysis
Have you ever been surprised when a price of a OTC Stock such as Integrated Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Integrated Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the OTC price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Integrated Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.63 | 5.51 | 1.07 | 0.20 | 11 Events / Month | 2 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.23 | 0.29 | 26.14 |
|
Integrated Biopharma Hype Timeline
Integrated Biopharma is currently traded for 0.23. The entity has historical hype elasticity of 1.07, and average elasticity to hype of competition of 0.2. Integrated is forecasted to increase in value after the next headline, with the price projected to jump to 0.29 or above. The average volatility of media hype impact on the company the price is about 111.76%. The price gain on the next news is projected to be 26.14%, whereas the daily expected return is currently at 0.63%. The volatility of related hype on Integrated Biopharma is about 1749.21%, with the expected price after the next announcement by competition of 0.43. The company currently holds 53 K in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Integrated Biopharma has a current ratio of 3.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Integrated Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Integrated Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Integrated Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Integrated to invest in growth at high rates of return. When we think about Integrated Biopharma's use of debt, we should always consider it together with cash and equity.Given the investment horizon of 90 days the next forecasted press release will be in about 11 days. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.Integrated Biopharma Related Hype Analysis
Having access to credible news sources related to Integrated Biopharma's direct competition is more important than ever and may enhance your ability to predict Integrated Biopharma's future price movements. Getting to know how Integrated Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Integrated Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PRRFY | Premier Foods Plc | 0.00 | 0 per month | 0.00 | 0.01 | 3.42 | (2.60) | 17.52 | |
| TQLB | Torque Lifestyle Brands | 0.00 | 0 per month | 8.33 | 0.07 | 22.00 | (19.67) | 73.22 | |
| NSPDF | Naturally Splendid Enterprises | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ARZTY | Aryzta AG PK | 0.00 | 0 per month | 0.00 | (0.07) | 3.41 | (3.23) | 10.62 | |
| CLBEY | Calbee Inc | 0.00 | 0 per month | 2.23 | 0.04 | 3.59 | (4.25) | 10.14 | |
| TSUKY | Toyo Suisan Kaisha | 0.00 | 0 per month | 1.92 | 0.07 | 5.73 | (3.94) | 10.45 | |
| THRN | Thorne HealthTech | 0.00 | 7 per month | 2.45 | 0.21 | 10.72 | (5.03) | 29.59 | |
| THS | Treehouse Foods | (1.08) | 8 per month | 0.00 | (0.13) | 2.18 | (2.56) | 17.71 | |
| PFODF | Premier Foods plc | 0.00 | 0 per month | 0.00 | 0.09 | 0.00 | 0.00 | 6.88 | |
| SMFL | Smart for Life | 4.23 | 9 per month | 0.00 | (0.08) | 19.72 | (15.61) | 58.69 |
Integrated Biopharma Additional Predictive Modules
Most predictive techniques to examine Integrated price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Integrated using various technical indicators. When you analyze Integrated charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Integrated Biopharma Predictive Indicators
The successful prediction of Integrated Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Integrated Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Integrated Biopharma based on analysis of Integrated Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Integrated Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Integrated Biopharma's related companies. Story Coverage note for Integrated Biopharma
The number of cover stories for Integrated Biopharma depends on current market conditions and Integrated Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Integrated Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Integrated Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Integrated Biopharma Short Properties
Integrated Biopharma's future price predictability will typically decrease when Integrated Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Integrated Biopharma often depends not only on the future outlook of the potential Integrated Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Integrated Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.9 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |